PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
3.56%
Cash & equivalents yoy growth below half of TRVN's 19.83%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
-100.00%
Short-term investments yoy growth ≥ 1.5x TRVN's -3.13%. David Dodd would see a more robust near-cash position, but confirm efficient allocation.
3.51%
Cash + STI yoy ≥ 1.5x TRVN's 2.17%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.27%
≥ 1.5x TRVN's 2.69%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
11.32%
0.5-0.75x TRVN's 15.76%. Martin Whitman might see a risk of falling behind in asset investment or shifting strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Less than half of TRVN's 0.19%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-18.41%
Below half of TRVN's 15.39%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
6.14%
≥ 1.5x TRVN's 2.74%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
65.90%
Less than half of TRVN's 185.94%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
126.86%
Less than half of TRVN's 6221.00%. David Dodd sees fewer expansions in other current obligations.
114.06%
Above 1.5x TRVN's 26.88%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
114.06%
Similar yoy to TRVN's 149.21%. Walter Schloss sees parallel expansions in total liabilities.
5.13%
Above 1.5x TRVN's 0.13%. Michael Burry suspects heavy new equity expansion or dilution.
-6.19%
0.5-0.75x TRVN's -9.26%. Martin Whitman is wary of weaker retention or lower profitability.
-12.13%
Less than half of TRVN's -585.51%. David Dodd sees fewer intangible or market-driven swings than competitor.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to TRVN's zero value, indicating worse performance.
-4.02%
Below half TRVN's -9.26%. Michael Burry sees potential underperformance in building shareholder capital.
6.14%
≥ 1.5x TRVN's 2.74%. David Dodd sees faster overall balance sheet growth than competitor.
-100.00%
≥ 1.5x TRVN's -3.13%. David Dodd sees far stronger investment expansions than competitor.
No Data
No Data available this quarter, please select a different quarter.
-2.49%
Less than half of TRVN's 23.27%. David Dodd sees better deleveraging or stronger cash buildup than competitor.